• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Coker Named Vice President of US Oncology Research

Coker Named Vice President of US Oncology Research

June 2, 2010
CenterWatch Staff

US Oncology, an integrated oncology company, has appointed Kevin Coker as the vice president of US Oncology Research, US Oncology’s site management organization and wholly-owned subsidiary.

Coker was most recently the director of Research Operations for Rocky Mountain Cancer Centers (RMCC), and was implemental in the growth of RMCC as a top program in the United Network of US Oncology. During Coker’s tenure, RMCC achieved distinction as one of the top accruing research sites in the network in 2008 and 2009, with a 43% increase in accruals by improving internal processes, implementing time-saving technology, reducing turnover and engaging team members in the mission and objectives.

Coker’s professional background also includes the University of Arkansas for Medical Sciences Clinical Research Center, where he implemented and facilitated more than 100 clinical research projects in three years, and time as an Assistant Attorney General at the Arkansas Attorney General’s Office.

Coker is a past member and chair of the Ethics Subcommittee for the Regulatory Affairs Professional Society. He currently serves as a member for the Board of Editors of Focus Magazine.

“I’m looking forward to this new position,” said Coker.  “Research is an integral part of US Oncology’s mission to advance cancer care, and I’m excited to push this mission even further.”

 “Grant Bogle, executive vice president, Strategy & Emerging Businesses, US Oncology, added: “US Oncology Research has made great strides in advancing high-quality cancer care to patients nation-wide including conducting 700 clinical trials and getting 40 drugs approved by the FDA.  Having Kevin’s work and expertise will only help in advancing our goals.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing